MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-026-16576-0

Медицинская библиотека · BMC cancer · 2026

Real-world efficacy and prognostic factor analysis of tislelizumab versus sintilimab in advanced non-small cell lung cancer.

Liu Quanyi, Zhu Xiaotong, Xie Yuxuan, Gu Yun, Shen Lei

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Tislelizumab and Sintilimab are commonly used immunotherapy drugs in clinical practice. Only a portion of advanced NSCLC patients achieve sustained remission and long-term survival through ICI immunotherapy, while others experience disease progression post-treatment. Selecting appropriate clinical therapies and predicting treatment efficacy remain significant challenges in clinical practice. By examining the clinical efficacy and safety of tislelizumab and sintilimab combined with chemotherapy in advanced NSCLC patients within real-world settings, and analyzing prognostic factors, this study aims to provide reference for clinical treatment decisions and prognosis assessment.

MATERIALS AND

METHODS

A retrospective analysis of clinical data from 212 patients with advanced NSCLC treated with the combination of tislelizumab or sintilimab plus chemotherapy in The First Affiliated Hospital of Dali University between March 1, 2022, and December 31, 2024. Patients were divided into the tislelizumab group (n = 124) and the sintilimab group (n = 88) based on the administered drug. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated in both groups. Kaplan-Meier methods were used to plot PFS and OS survival curves. Univariate analysis was performed using the Log-rank test, and Cox regression models were employed to identify independent prognostic factors for PFS and OS.

RESULTS

The median progression-free survival (mPFS) in the tislelizumab group and the sintilimab group was 14.0 months (95% CI: 11.79-16.21) and 7.0 months (95% CI: 4.31-9.69), respectively (P = 0.005). The difference in mPFS between the two groups was statistically significant. The median overall survival (mOS) was 27.0 months (95% CI: 20.03-33.97) and 24.0 months (95% CI: 13.85-34.15) (P = 0.113), with no statistically significant difference in mOS between groups. ORR was 39.52% versus 18.18% (P < 0.001), showing a statistically significant difference; DCR was 66.13% versus 70.54% (P = 0.506), with no statistically significant difference. After adjustment for confounders, multivariable Cox regression revealed no significant differences between the two agents for PFS (HR = 1.128, 95% CI 0.596-2.133, P = 0.712) or OS (HR = 0.664, 95% CI 0.378-1.165, P = 0.153). ADR occurrence showed a borderline association with improved OS (HR = 0.569, P = 0.093), but was not statistically significant. ALI, PNI, anti-angiogenic combination, and treatment line were not independent prognostic factors (all P > 0.05).

CONCLUSION

In real-world clinical settings, tislelizumab combined with chemotherapy may bring potential improvements in objective response rate and progression-free survival in the short term for patients with advanced NSCLC. Nevertheless, sintilimab and tislelizumab exert comparable long-term survival benefits when used in combination with chemotherapy. After adjusting for confounding factors via multivariable regression analysis, no significant survival differences were confirmed between the two treatment regimens. Further prospective clinical studies with longer follow-up are required to verify the above conclusions.

Для цитирования: Liu Quanyi, Zhu Xiaotong, Xie Yuxuan, Gu Yun, Shen Lei. Real-world efficacy and prognostic factor analysis of tislelizumab versus sintilimab in advanced non-small cell lung cancer.. BMC cancer. 2026. DOI: 10.1186/s12885-026-16576-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.